Biosimilar infliximab for Behcet's syndrome: a case series
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.37, sa.6, ss.111-115, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 37 Sayı: 6
- Basım Tarihi: 2019
- Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.111-115
- Anahtar Kelimeler: Behcet's syndrome, bio-similar, infliximab, DISEASE, RECOMMENDATIONS, MULTICENTER, EFFICACY
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.